Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004105 · ClinicalTrials.gov registry record · Phase 1
Combination Chemotherapy in Treating Patients With Advanced Cancer
A Phase 1 study, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00004105 is a Phase 1 study that has completed, run by NYU Langone Health.
The verdict
NCT00004105, a Phase 1 study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase I/II trial to study the effectiveness of vinorelbine, paclitaxel, and estramustine in treating patients who have advanced cancer that has not responded to previous treatment.
Interventions
- DRUG paclitaxel
- DRUG estramustine phosphate sodium
- DRUG vinorelbine ditartrate
Trial Details
| Field | Value |
|---|---|
| Start Date | 1998-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004105
The ClinicalTrials.gov registry entry for NCT00004105 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which paclitaxel is the first listed.
NCT00004105 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00004105 about?
NCT00004105 is a clinical study titled "Combination Chemotherapy in Treating Patients With Advanced Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase I/II trial to study the effectiveness of vinorelbine, paclitaxel, and estramustine in treating patients wh...
What is the current status of trial NCT00004105?
This trial is currently completed. It is a Phase 1 study. The study started on 1998-09.
What interventions are being tested in trial NCT00004105?
The interventions under investigation include: paclitaxel (DRUG), estramustine phosphate sodium (DRUG), vinorelbine ditartrate (DRUG).
Who is sponsoring clinical trial NCT00004105?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.